Teva's Q2 revenues flat on European rise, U.S. fall

The good news from Teva Pharmaceutical Industries: Last year's acquisition of Ratiopharm hiked European sales for the second quarter. The not-so-good: A lack of new product introductions and erosion in sales of key products offset that rise, leaving sales flat. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.